Comments
Loading...
GSK Analyst Ratings and Price Targets | NYSE:GSK | Benzinga
GSK PLC has a consensus price target of $45.5 based on the ratings of 5 analysts. The high is $47 issued by Goldman Sachs on May 30, 2024. The low is $44 issued by Morgan Stanley on January 23, 2024. The 3 most-recent analyst ratings were released by Jefferies, Goldman Sachs, and Morgan Stanley on July 2, 2024, May 30, 2024, and January 23, 2024, respectively. With an average price target of $48 between Jefferies, Goldman Sachs, and Morgan Stanley, there's an implied 25.05% upside for GSK PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for GSK
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/12/2024 | Buy Now | — | Jefferies | Peter Welford57% | — | Downgrade | Buy → Hold | Get Alert |
| 10/31/2024 | Buy Now | — | Guggenheim | Seamus Fernandez62% | — | Downgrade | Buy → Neutral | Get Alert |
| 07/08/2024 | Buy Now | — | UBS | Jo Walton9% | — | Downgrade | Buy → Neutral | Get Alert |
| 07/02/2024 | Buy Now | 38.07% | Jefferies | Peter Welford57% | $52.5 → $53 | Maintains | Buy | Get Alert |
| 05/30/2024 | Buy Now | 22.44% | Goldman Sachs | Rajan Sharma26% | → $47 | Initiates | → Neutral | Get Alert |
| 03/04/2024 | Buy Now | — | Guggenheim | Seamus Fernandez62% | — | Upgrade | Neutral → Buy | Get Alert |
| 01/23/2024 | Buy Now | 14.63% | Morgan Stanley | Mark Purcell30% | → $44 | Initiates | → Equal-Weight | Get Alert |
| 01/03/2024 | Buy Now | 25.05% | Jefferies | Peter Welford57% | $38.5 → $48 | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for GSK (GSK) stock?
The latest price target for GSK (NYSE:GSK) was reported by Jefferies on November 12, 2024. The analyst firm set a price target for $0.00 expecting GSK to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for GSK (GSK)?
The latest analyst rating for GSK (NYSE:GSK) was provided by Jefferies, and GSK downgraded their hold rating.
When was the last upgrade for GSK (GSK)?
The last upgrade for GSK PLC happened on March 4, 2024 when Guggenheim raised their price target to N/A. Guggenheim previously had a neutral for GSK PLC.
When was the last downgrade for GSK (GSK)?
The last downgrade for GSK PLC happened on November 12, 2024 when Jefferies changed their price target from N/A to N/A for GSK PLC.
When is the next analyst rating going to be posted or updated for GSK (GSK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of GSK, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for GSK was filed on November 12, 2024 so you should expect the next rating to be made available sometime around November 12, 2025.
Is the Analyst Rating GSK (GSK) correct?
While ratings are subjective and will change, the latest GSK (GSK) rating was a downgraded with a price target of $0.00 to $0.00. The current price GSK (GSK) is trading at is $38.39, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.